论文部分内容阅读
目的 本研究旨在探讨SDZPSC833和维拉帕米 (verapamil,VER)对丝裂霉素 (MMC)体外增效作用。方法 以人宫颈癌Hela细胞和耐药亚系Hela/MMC细胞为材料 ,观察了SDZPSC833和VER对MMC体外增效作用。结果 无毒剂量的SDZPSC833和VER ( 13mg/L)可显著增加MMC的细胞毒作用且可基本克服Hela/MMC细胞对MMC 5 0 2倍的耐药 ;3H -TdR实验表明 ,VER或SDZPSC833与MMC联用可增加MMC对宫颈癌细胞DNA合成的抑制 ,且SDZPSC833作用强于VER ,光镜和电镜下形态学观察 ,联合用药组细胞呈明显退行性变。结论 无毒剂量的SDZPSC833和VER体外能基本逆转Hela/MMC细胞对MMC的耐药性 ,且SDZPSC833作用强于VER。SDZPSC833作为耐药修饰剂可望用于宫颈癌化疗 ,其临床应用前景优于VER。
Objective This study aimed to investigate the synergistic effects of SDZPSC833 and verapamil (VER) on mitomycin (MMC) in vitro. Methods Human cervical cancer Hela cells and drug-resistant Hela / MMC cells were used as materials to observe the synergistic effects of SDZPSC833 and VER on MMC in vitro. Results The non-toxic SDZPSC833 and VER (13mg / L) significantly increased the cytotoxicity of MMC and overcame the resistance of Hela / MMC to MMC at 50 2 times. 3H-TdR assay showed that VER or SDZPSC833 combined with MMC Combination of MMC can increase the inhibition of DNA synthesis of cervical cancer cells, and the role of SDZPSC833 stronger than VER, light microscope and electron microscopy morphological observation, the combination of cells was significantly degenerative changes. Conclusion The non-toxic dose of SDZPSC833 and VER can basically reverse the drug resistance of Hela / MMC cells to MMC, and the effect of SDZPSC833 is stronger than that of VER. SDZPSC833 as a drug-resistant modifier is expected for cervical cancer chemotherapy, its clinical application is better than VER.